Our analysis results show that NSCLC patients with PD-L1-negative expression (TC0 and IC0) can have improved OS from atezolizumab, and we recommend that these patients use atezolizumab as a 1st-line monotherapy. This evidence concerns the gene CD274 and non-small cell lung carcinoma.